T-1101 be invited for an oral presentation at the 19th Annual Congress of International Drug DiscoveryScience & Technology (IDDST-2023)

Project / By

The discovery and development of our first-in-class Hec1/Nek2 inhibitor, oral anti-cancer drug T-1101 (Tosylate), have been accepted for an oral presentation at the 19th Annual Congress of International Drug DiscoveryScience & Technology (IDDST-2023).